Ironwood Pharmaceuticals
IRWD
155 hedge funds and large institutions have $105M invested in Ironwood Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 60 increasing their positions, 51 reducing their positions, and 64 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 51
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.8% less ownership
Funds ownership: 97.15% → 90.35% (-6.8%)
23% less funds holding
Funds holding: 200 → 155 (-45)
54% less capital invested
Capital invested by funds: $229M → $105M (-$124M)
70% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.07M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.86M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.7M |
| 4 |
AC
Armistice Capital
New York
|
+$1.92M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$9.74M |
| 2 |
Millennium Management
New York
|
-$4.92M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$2.63M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.25M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$1.8M |
IRWD Hedge Fund Activity: Q2 2025 in Review
155 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2025, worth a combined $105M — down 54% from $229M a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of IRWD and 19 opened new positions — a net loss of 45 holders — while 51 trimmed existing stakes and 60 added.
The largest buyer was Acadian Asset Management, adding an estimated $3.07M. The largest seller was Braidwell, exiting entirely with an estimated $9.74M sold.
- 155 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2025, down from 200 in Q1 2025.
- Funds reported $105M of Ironwood Pharmaceuticals stock for Q2 2025, down 54% quarter-over-quarter.
- 19 funds opened new Ironwood Pharmaceuticals positions in Q2 2025 and 64 closed out, a net change of -45 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2025 was Acadian Asset Management, an estimated $3.07M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2025 was Braidwell, an estimated $9.74M sold.
Based on aggregated 13F filings for Q2 2025.